Drug companies told that sponsoring patients' groups might help win approval for their products.
作者信息
Burton Bob
出版信息
BMJ. 2005 Dec 10;331(7529):1359. doi: 10.1136/bmj.331.7529.1359-b.
Abstract
摘要
相似文献
1
Drug companies told that sponsoring patients' groups might help win approval for their products.制药公司被告知，赞助患者团体可能有助于其产品获得批准。
BMJ. 2005 Dec 10;331(7529):1359. doi: 10.1136/bmj.331.7529.1359-b.
2
Should patient groups accept money from drug companies? Yes.患者群体应该接受制药公司的资金吗？应该接受。
BMJ. 2007 May 5;334(7600):934. doi: 10.1136/bmj.39185.461968.AD.
3
Should patient groups accept money from drug companies? No.患者群体应该接受制药公司的资金吗？不应该。
BMJ. 2007 May 5;334(7600):935. doi: 10.1136/bmj.39185.394005.AD.
4
User fees for faster drug reviews. Are they helping or hurting the public health?加快药品审评的用户付费。它们对公众健康是有帮助还是有损害？
FDA Consum. 2000 Sep-Oct;34(5):25-9.
5
Sponsorship of patients' groups by drug companies should be made transparent.制药公司对患者团体的资助应予以透明化。
BMJ. 2006 Dec 16;333(7581):1238. doi: 10.1136/bmj.39062.360289.DB.
6
Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.加拿大和澳大利亚制药公司用户费与药品批准之间的关系：一项生成假设的研究。
Ann Pharmacother. 2006 Dec;40(12):2216-22. doi: 10.1345/aph.1H117. Epub 2006 Nov 28.
7
Relationships between the pharmaceutical industry and patients' organisations.制药行业与患者组织之间的关系。
BMJ. 2003 May 31;326(7400):1208-10. doi: 10.1136/bmj.326.7400.1208.
8
The illusion of invulnerability.刀枪不入的错觉。
BMJ. 2007 May 19;334(7602):1020. doi: 10.1136/bmj.39212.696238.3A.
9
Does R&D pay?研发有回报吗？
Drug Discov Today. 2010 Mar;15(5-6):230-4. doi: 10.1016/j.drudis.2009.11.002. Epub 2009 Nov 30.
10
Guidelines for measuring the costs and consequences of adopting new pharmaceutical products: are they on track?衡量采用新药品的成本与后果的指南：它们步入正轨了吗？
Med Decis Making. 1998 Apr-Jun;18(2 Suppl):S19-22.
引用本文的文献
1
Information About Canadian Patient Groups' Conflicts of Interest and Industry Funding-Incomplete, Inconsistent, and Unreliable: A Cross-Sectional Study.关于加拿大患者群体利益冲突和行业资助的信息——不完整、不一致且不可靠：一项横断面研究。
Int J Soc Determinants Health Health Serv. 2025 Jul;55(3):352-367. doi: 10.1177/27551938251325801. Epub 2025 Mar 17.
2
Commercial influences on patient and public involvement: a renewed call for research and action.商业对患者及公众参与的影响：对研究与行动的再次呼吁。
Health Promot Int. 2024 Dec 1;39(6). doi: 10.1093/heapro/daae188.
3
Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.加拿大患者群体的商业资助与其对药品资助看法之间的关联：一项观察性研究。
PLoS One. 2019 Feb 15;14(2):e0212399. doi: 10.1371/journal.pone.0212399. eCollection 2019.
4
Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.患者倡导组织：制度性利益冲突、信任和值得信赖。
J Law Med Ethics. 2013 Fall;41(3):680-7. doi: 10.1111/jlme.12078.
5
Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries.患者组织和药品报销流程：八个欧洲国家的探索性研究。
BMC Health Serv Res. 2010 Feb 22;10:45. doi: 10.1186/1472-6963-10-45.
6
Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.患者组织网站上的资金广告与披露：一项横断面调查。
BMC Public Health. 2006 Aug 3;6:201. doi: 10.1186/1471-2458-6-201.
Zotero 插件